Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic
The COVID-19 pandemic has brought virology to the forefront of many research programs. But how do we get ahead of the next viral threat? Limited commercial labs are licensed to conduct research using BSL-3 or BSL-4 pathogens. However, reporter virus tools such as ready-to-use Reporter Virus Particles (RVPs, i.e., pseudoviruses) have enabled virus research in a BSL-2 environment, allowing testing of sera and antibodies in high-throughput, safe neutralization assays to accelerate virology research.
In this GEN webinar, one of our distinguished speakers, Dr. Hayley Crawford, will discuss Integral Molecular’s broad catalog of RVPs, including influenza A and B, Marburg virus, and the latest variants of SARS-CoV-2. Moreover, she will discuss Integral Molecular’s expertise in custom RVP projects. Additionally, panelists Dr. Sheila Keating and Dr. Natalie Anosova will describe how Integral Molecular’s extensive collection of SARS-CoV-2 variant RVPs enabled them to meet the most recent FDA guidance for variant testing of vaccines and therapeutic antibodies.
Jeff Buguliskis, PhD, Technical Editor, Genetic Engineering & Biotechnology News
Haley Crawford, PhD, Virology Research & Applications Specialist, Integral Molecular
Dr. Crawford discusses how you can facilitate safe and reproducible neutralization assays using RVPs.
Sheila M. Keating, PhD, MSPH, Vice President of Immunology, GigaGen
Dr. Keating describes how GigaGen used RVP neutralization assays in developing an antibody therapeutic against SARS-CoV-2.
Natalie Anosova, PhD, Director Immunology, Head of Preclinical Immunobiology, Sanofi
Dr. Anosova describes how Sanofi used RVPs in the development of a SARS-CoV-2 vaccine candidate.
Explore our customer stories in depth through publications covering work described in the webinar.
- GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2 Mizrahi et al. 2022 Pathogens 11, 806
- Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model Kalnin et al. 2022 Vaccine 40, 1289–1298
- Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models Kalnin et al. 2021 NPJ Vaccines 6
- Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates Pavot et al. 2022 Nature Communications 13, 1699